Abstract:The agenda of pharmacology discovery in the field of personalized oncology was dictated by the search of molecular targets assumed to deterministically drive tumor development. In this perspective, genes play a fundamental "causal" role while cells simply act as causal proxies, i.e., an intermediate between the molecular input and the organismal output. However, the ceaseless genomic change occurring across time within the same primary and metastatic tumor has broken the hope of a personalized treatment based only upon genomic fingerprint. Indeed, current models are unable in capturing the unfathomable complexity behind the outbreak of a disease, as they discard the contribution of non-genetic factors, environment constraints, and the interplay among different tiers of organization. Herein, we posit that a comprehensive personalized model should view at the disease as a "historical" process, in which different spatially and timely distributed factors interact with each other across multiple levels of organization, which collectively interact with a dynamic gene-expression pattern. Given that a disease is a dynamic, non-linear process - and not a static-stable condition - treatments should be tailored according to the "timing-frame" of each condition. This approach can help in detecting those critical transitions through which the system can access different attractors leading ultimately to diverse outcomes - from a pre-disease state to an overt illness or, alternatively, to recovery. Identification of such tipping points can substantiate the predictive and the preventive ambition of the Predictive, Preventive and Personalized Medicine (PPPM/3PM). However, an unusual effort is required to conjugate multi-omics approaches, data collection, and network analysis reconstruction (eventually involving innovative Artificial Intelligent tools) to recognize the critical phases and the relevant targets, which could help in patient stratification and therapy personalization.

Targeted therapies: how personal should we go?

Personalized Medicine: Recent Progress in Cancer Therapy

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

Advances in Targeted Therapy for Cancer: Precision Medicine Approaches

Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches

Personalization of medical treatments in oncology: time for rethinking the disease concept to improve individual outcomes

Advances in Personalized Oncology

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

A Review of Personalized Therapeutic Strategies

Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy

Targeted Therapies and Drug Resistance in Advanced Breast Cancer, Alternative Strategies and the Way beyond

Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends

Personalizing chemotherapy dosing using pharmacological methods

The importance of personalized medicine in urological cancers

Breast cancer immunotherapy and personalized medicine

The Way Forward for Personalized Treatment? A Single-Center Experience

The role of targeted therapy and biomarkers in breast cancer treatment

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer

Personalized medicine: Clinical oncology on molecular view of treatment